GlaxoSmithKline Share Price (GSK)

1,430.00 +22.60 (+1.61%) delayed: 11:59PM BST
Bid price 1,427.80 Open price 1,419.00
Ask price 1,430.00 Prev close 1,430.00
High price 1,435.00 Spread 0.15%
Low price 1,412.53 Volume 9,782,267

Register now for FREE live GlaxoSmithKline share prices, GlaxoSmithKline stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get GlaxoSmithKline Level 2 Data, indepth research tools and investor commentary for GlaxoSmithKline (GSK) and other London Stock Exchange equities.

GlaxoSmithKline Share Price Chart

Advanced Charts >>

Register now for FREE GlaxoSmithKline share price charts

GlaxoSmithKline Share Price Information

Name GlaxoSmithKline Epic GSK
Sector Pharmaceuticals & Biotechnology ISIN GB0009252882
Activites GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment. Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products. The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders. GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Around 35,000 employees work at 82 manufacturing sites in 37 countries and over 15,000 are in R&D. GSK R&D is based at 24 sites in 11 countries. The company has a leading position in genomics/genetics and new drug discovery technologies. The GSK R&D budget is about £2.8bn/$5bn. Index FTSE 100

GlaxoSmithKline Key Numbers

Latest Share Price (p) 1,430.00 Net Gearing (%) 87.01
Market Capitalisation (£m) 69,792.44 Gross Gearing (%) 93.81
Shares in issue (m) 4,958.96 Debt Ratio 88.30
P/E Ratio 44.82 Debt-to-Equity Ratio 0.50
Total dividends per share (p) 80.00 Assets / Equity Ratio 16.16
Dividend Yield (%) 5.68 Price to book value 20.00
Dividend cover (x) 0.39 ROCE (%) 11.82
Earning per share (p) 31.40 EPS Growth (%) 67.02
52 week high / low 1,724.50 / 1,236.40 DPS Growth (%) 0.00

GlaxoSmithKline Director Deals

Dec.Date Type Director Pos No. of Shares
17/04/2018 DRIP Simon Dingemans FD 1,818
17/04/2018 DRIP Emma Walmsley CEO 1,987
17/04/2018 DRI Emma Walmsley CEO 1,885
17/04/2018 DRIP Simon Dingemans FD 13,474
17/04/2018 DRIP Emma Walmsley CEO 16,583

More GlaxoSmithKline Director Deals >>

GlaxoSmithKline Company News

15:15 20/04/2018

Director/PDMR Shareholding

RNS Number : 6719L GlaxoSmithKline PLC 20 April 2018   GlaxoSmithKline plc   (the   ' Company ')   Transaction notification   1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr B McNamara...

15:15 20/04/2018

Director/PDMR Shareholding

RNS Number : 6713L GlaxoSmithKline PLC 20 April 2018   GlaxoSmithKline plc   (the   ' Company ')   Transaction notification     1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr N Hirons...

07:51 19/04/2018

GlaxoSmithKline IMPACT study shows significant benefits of Trelegy Ellipta for COPD patients

GlaxoSmithKline and Innoviva said Thursday that the landmark IMPACT study published in the New England Journal of Medicine or NEJM showed significant benefits of Trelegy Ellipta for patients with chronic obstructive pulmonary disease or COPD. The study showed that Trelegy Ellipta was superior to...

More GlaxoSmithKline Company News >>

Register now for FREE GlaxoSmithKline company news

GlaxoSmithKline Share Price Discussions

more than 1 year ago

Glaxo trading near low (GSK)

there seems to be some heavy resistance around these level with a lot of potential upside.

more than 1 year ago

Traders Thread - Friday 13th February (GSK)

UK PreMarket Futures FTSE +8 DAX Unch DOW +26 S&P +2 Nasdaq +5 1 Day 2 Day...

more than 1 year ago

Traders Thread - Friday 13th February (GSK)

UK PreMarket Futures FTSE +8 DAX Unch DOW +26 S&P +2 Nasdaq +5 1 Day 2 Day...

Register now for FREE GlaxoSmithKline share price discussions